Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Maturitas. 2018 Sep 14;117:64–77. doi: 10.1016/j.maturitas.2018.09.002

Table 1.

Case-control analyses in the overall sample (all ages, all indications).

Characteristica Bilateral
Oophorectomy
(n=1,653)
Control Women
(n=1,653)
Adjusted
Odds Ratio
(95% Cl)b
p Value
N % N %
Age at menarchec
 <12 147 9.8 135 10.0 1.00 (reference) --
 12 548 36.7 458 34.0 1.17(0.87, 1.58) 0.30
 13 572 38.3 488 36.3 1.06(0.79, 1.42) 0.70
 >13 226 15.1 265 19.7 0.79(0.57, 1.10) 0.16
Oral contraceptive use (ever vs. never)d 841 50.9 1,000 60.5 0.65 (0.57, 0.75) <0.001
Years of oral contraceptive usec,e
 0 or <0.5 812 51.3 653 42.1 1.00 (reference) --
 0.5–4.9 402 25.4 349 22.5 0.90(0.75, 1.08) 0.26
 ≥5.0 369 23.3 550 35.4 0.51 (0.43, 0.61) <0.001
Gravidityc
 0d 253 15.3 227 13.7 1.00 (reference) --
 1 164 9.9 179 10.8 0.82(0.62, 1.09) 0.17
 2 496 30.0 481 29.1 0.91 (0.73, 1.14) 0.40
 ≥3 740 44.8 766 46.3 0.86(0.70, 1.07) 0.17
Twin or multiple gestationd 42 2.5 33 2.0 1.25(0.79, 1.98) 0.34
Pregnancy lossd 550 33.3 531 32.1 1.07(0.92, 1.25) 0.36
Induced abortiond,f 92 5.6 118 7.1 0.77(0.58, 1.02) 0.07
Spontaneous abortion or still birthd 488 29.5 454 27.5 1.13(0.96, 1.32) 0.13
Parityc
 0d 313 18.9 279 16.9 1.00 (reference) --
 1 194 11.7 216 13.1 0.80(0.62, 1.04) 0.09
 2 619 37.4 595 36.0 0.91 (0.74, 1.11) 0.35
 ≥3 527 31.9 563 34.1 0.83(0.67, 1.02) 0.08
Breast feeding 493 40.8 655 51.2 0.68(0.56, 0.81) <0.001
lnfertilityd 292 17.7 164 9.9 1.95(1.59, 2.40) <0.001
Fibrocystic breast diseased 1,083 65.5 1,128 68.2 0.85(0.72, 1.00) 0.047
Smoking statusc
 Neverd 897 54.3 957 57.9 1.00 (reference) --
 Former 393 23.8 377 22.8 1.06(0.90, 1.26) 0.49
 Current 363 22.0 319 19.3 1.15(0.96, 1.39) 0.13
Pack-yearsc,e
 0 897 54.6 957 59.1 1.00 (reference) --
 0.1–5.9 180 10.9 167 10.3 1.11 (0.88, 1.40) 0.39
 ≥6.0 567 34.5 495 30.6 1.16(0.99, 1.36) 0.06
Height (cm)c,e
 <161.0 509 30.8 529 32.1 1.00 (reference) --
 161.0–166.9 602 36.4 579 35.2 1.04(0.87, 1.23) 0.67
 ≥167.0 542 32.8 538 32.7 1.01 (0.85, 1.21) 0.92
Weight (kg)c,e
 <64.0 455 27.5 573 35.0 1.00 (reference) --
 64.0–78.9 556 33.6 564 34.5 1.23(1.03, 1.46) 0.02
 ≥79.0 642 38.8 499 30.5 1.58(1.32, 1.89) <0.001
Body mass index (kg/m2)c
 <25.0 596 36.1 700 42.9 1.00 (reference) --
 25.0–29.9 481 29.1 488 29.9 1.17(0.99, 1.39) 0.07
 ≥30.0 576 34.8 442 27.1 1.51 (1.27, 1.79) <0.001
a

Women with missing or unknown data were not included in the respective analysis for the following characteristics: 467 for age at menarche (160 cases and 307 controls), 171 for years of birth control use (70 cases and 101 controls), 817 for breast feeding status (444 cases and 373 controls), 43 for smoking pack-years (9 cases and 34 controls), and 23 women for height, weight, and/or body mass index (0 cases and 23 controls).

b

The odds ratios and confidence intervals for each characteristic were calculated using conditional logistic regression models (matched pairs) adjusted for years of education (≤12; 13–16; >16), race (white; non-white) and quartiles of household income (<$42,000; $42,000–56,999; $57,000–71,999; ≥$72,000). Women with unknown education (3 cases and 35 controls) were assigned to the ≤12 years group, and women with unknown income (6 cases and 2 controls) were assigned to the $42,000–56,999 group (second quartile).

c

Ordinal characteristics were also tested for dose-effect (i.e., linear) trends adjusted for years of education, race, and household income: age at menarche (p=0.02), years of oral contraceptive use (p<0.001), gravidity (p=0.31), parity (p=0.18), smoking status (p=0.13), pack-years (p=0.06), height (p=0.93), weight (p<0.001), and body mass index (p<0.001).

d

For these characteristics, women with missing or unknown data were included in the no exposure category.

e

Years of oral contraceptive use, smoking pack-years, height, and weight were stratified using tertiles calculated from the overall sample (case-control groups pooled).

f

We may have underestimated induced abortions performed outside of the medical care facilities included in the REP.